Up a level |
Wharton, Sean, Astrup, Arne, Endahl, Lars, Lean, Michael EJ, Satylganova, Altynai, Skovgaard, Dorthe, Wadden, Thomas A and Wilding, John PH ORCID: 0000-0003-2839-8404
(2021)
Estimating and reporting treatment effects in clinical trials for weight management: using estimands to interpret effects of intercurrent events and missing data.
INTERNATIONAL JOURNAL OF OBESITY, 45 (5).
pp. 923-933.
O'Neil, Patrick M, Aroda, Vanita R, Astrup, Arne, Kushner, Robert, Lau, David CW, Wadden, Thomas A, Brett, Jason, Cancino, Ana-Paula and Wilding, John PH ORCID: 0000-0003-2839-8404
(2017)
Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials.
DIABETES OBESITY & METABOLISM, 19 (11).
pp. 1529-1536.
Wilding, John PH ORCID: 0000-0003-2839-8404, Batterham, Rachel L, Calanna, Salvatore, Davies, Melanie, Van Gaal, Luc F, Lingvay, Ildiko, McGowan, Barbara M, Rosenstock, Julio, Tran, Marie TD, Wadden, Thomas A et al (show 4 more authors)
(2021)
Once-Weekly Semaglutide in Adults with Overweight or Obesity.
NEW ENGLAND JOURNAL OF MEDICINE, 384 (11).
pp. 989-1002.
Kushner, Robert F, Calanna, Salvatore, Davies, Melanie, Dicker, Dror, Garvey, W Timothy, Goldman, Bryan, Lingvay, Ildiko, Thomsen, Mette, Wadden, Thomas A, Wharton, Sean et al (show 2 more authors)
(2020)
Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5.
OBESITY, 28 (6).
pp. 1050-1061.
Wilding, John PH ORCID: 0000-0003-2839-8404, Batterham, Rachel L, Davies, Melanie, Van Gaal, Luc F, Kandler, Kristian, Konakli, Katerina, Lingvay, Ildiko, McGowan, Barbara M, Oral, Tugce Kalayci, Rosenstock, Julio et al (show 4 more authors)
(2022)
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.
DIABETES OBESITY & METABOLISM, 24 (8).
pp. 1553-1564.